|
|
Vaccine Detail
|
mRNA-electroporated dendritic cells encoding gp100 and tyrosinase as melanoma vaccine |
| Vaccine Information |
- Vaccine Name: mRNA-electroporated dendritic cells encoding gp100 and tyrosinase as melanoma vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004614
- Type: Dendritic cell
- Status: Research
- Antigen: tumor-associated antigens: antigen G250 with gp100 and tyrosinase protein, and pulsed with keyhole limped hemocyan (KLH) protein.
- CA9
gene engineering:
- Preparation: Monocyte-derived DC, electroporated with mRNA encoding gp100 and tyrosinase, were pulsed with keyhole limpet hemocyanin and administered intranodally (Aarntzen et al., 2012).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Vaccination with mRNA-electroporated DC induces a broad repertoire of IFNγ producing TAA-specific CD8(+) and CD4(+) T-cell responses, particularly in stage III melanoma patients (Aarntzen et al., 2012).
|
| References |
Aarntzen et al., 2012: Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(19); 5460-5470. [PubMed: 22896657].
|
|
